Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis

1Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To fight against coronavirus disease 2019 (COVID-19), the vaccination is currently the most effective approach. However, in addition to common systemic side effects, the vaccines can cause serious allergic reactions or anaphylaxis. In anaphylaxis, the exposure to the allergen causes a sudden release of chemical mediators from mast cells, for which adrenaline is the drug of first choice. In our previous basic studies, in addition to adrenaline, anti-allergic drugs (olopatadine, loratadine, tranilast and ketotifen), antibiotics (clarithromycin), corticosteroids (hydrocortisone and dexamethasone) and certain food constituents (caffeine and catechin) inhibited the process of exocytosis and showed their effectiveness as highly potent mast cell stabilizers. In these studies, since mast cells were pre-incubated with these drugs or the food constituents before exocytosis was induced, the findings strongly indicated their prophylactic efficacy in stabilizing mast cells. Considering such pharmacological properties of these commonly prescribed medications or the food constituents, their prophylactic use may potentially be beneficial in preventing anaphylaxis caused by COVID-19 vaccination.

Cite

CITATION STYLE

APA

Kazama, I. (2021, December 1). Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis. Clinical and Molecular Allergy. BioMed Central Ltd. https://doi.org/10.1186/s12948-021-00162-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free